

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH, 2005

	(Rs. lakhs)		
	Unaudited		Audited
	3 months ended 31.03.2005	3 months ended 31.03.2004	Year ended 31.12.2004
Sales	29611	38934	147959
Less: Excise Duty on Sales	<u>1987</u>	<u>2996</u>	<u>10370</u>
Net Sales	27624	35938	137589
Other Income	823	433	2421
Interest Income (net)	548	803	2668
Total Income	28995	37174	142678
Materials Consumed			
(Increase) / decrease in stock-in-trade	(2630)	3554	(318)
Consumption of raw and packing materials and purchase of finished goods	<u>14110</u>	<u>13152</u>	<u>59404</u>
Total Materials Consumed	11480	16706	59086
Excise Duty on Samples and (Increase) / Decrease in Stock-in-Trade	170	(381)	1241
Staff Cost	3560	3534	14408
Other Expenditure	5514	6129	25071
Recovery of Expenses	(197)	(165)	(699)
Total Expenditure	20527	25823	99107
Depreciation	373	408	1747
Profit before Tax and Exceptional Items	8095	10943	41824
Provision for Taxation - Current tax	2540	3895	13964
- Deferred tax	80	61	1255
Net Profit after Tax before Exceptional Items	5475	6987	26605
Exceptional Items (net of tax)	(784)	(589)	6704
Net Profit	4691	6398	33309
Paid-up Equity Share Capital (Face value per share Rs. 10)	8732	8732	8732
Reserves excluding Revaluation Reserves			83694
Earnings per Share before Exceptional Items (Rs.)	6.3	8.0	30.5
Earnings per Share / Diluted Earnings per Share (Rs.)	5.4	7.3	38.1
Aggregate of Non-promoter Shareholding :			
Number of Shares	44405058	44405058	44405058
% of Shareholding	51%	51%	51%

1. Destocking by the trade during the quarter ended 31st March, 2005 because of uncertainties over VAT has resulted in Net Sales for the quarter being lower by 23% as compared to the corresponding period last year.
2. Exceptional Items for the quarter ended 31st March, 2005 are mainly in respect of a claim pertaining to formulations pricing. The figure for the quarter ended 31st March, 2004 relates mainly to costs of separation and retirement benefits of the management staff at the Bangalore factory.
3. The Company has announced its intention to Buyback its Equity Shares upto a limit not exceeding Rs. 230,65.21 lakhs being 25% of the existing Paid-up Share Capital and Free Reserves of the Company, at a price not exceeding Rs. 800 per Equity Share from the open market through stock exchanges. The necessary approval of the shareholders has been obtained through a Postal Ballot.
4. There were no Investor complaints pending as at the beginning of the quarter. The Company has received 39 complaints mainly in respect of non-receipt of Annual Report and Dividend from the Investors during the quarter and all of them have since been resolved.
5. The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 29th April, 2005. The statutory auditors have carried out a limited review of the results for the three months ended 31st March, 2005. The figures for the three months ended 31st March, 2004 include the figures of erstwhile Burroughs Wellcome (India) Limited and have been regrouped wherever necessary to facilitate comparison.

By Order of the Board

S. Kalyanasundaram
Managing Director

29th April, 2005